Drug treatment for early-stage COPD

New England Journal of Medicine

Volumn 377, Issue 10, 2017, Pages 988-989

  Ko, Fanny W S ^a   Wong, Gary W K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; TIOTROPIUM BROMIDE;

ASYMPTOMATIC DISEASE; CHRONIC COUGH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COPD ASSESSMENT TEST SCORE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG USE; DYSPNEA; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; HUMAN; INCIDENCE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SHORT SURVEY; SPUTUM; SYMPTOM; TREATMENT RESPONSE;

FORCED EXPIRATORY VOLUME; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 85029233012     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1707929     Document Type: Short Survey

References (10)

1. Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health 2015; 5(2): 020415.
2. Tilert T, Dillon C, Paulose-Ram R, Hnizdo E, Doney B. Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: The National Health and Nutrition Examination Survey (NHANES) 2007-2010. Respir Res 2013; 14: 103.
3. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: Updated 2017 (http://goldcopd .org/ gold-2017-global-strategy-diagnosis-management-prevention -copd/ ).
4. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): A population-based prevalence study. Lancet 2007; 370: 741-50.
5. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): A prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-8.
6. Johansson G, Lindberg A, Romberg K, Nordstrom L, Gerken F, Roquet A. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Respir J 2008; 17: 169-75.
7. Tashkin DP, Celli BR, Decramer M, Lystig T, Liu D, Kesten S. Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT trial. COPD 2012; 9: 289-96.
8. Zhou Y, Zhong N, Li X, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med 2017; 377: 923-35.
9. Zeng G, Sun B, Zhong N. Non-smoking-related chronic obstructive pulmonary disease: A neglected entity? Respirology 2012; 17: 908-12
10. US Preventive Services task Force. Screening for chronic obstructive pulmonary disease: US Preventive Services Task Force recommendation statement. JAMA 2016; 315: 1372-7.